- Teams plan to cooperate on the development of a machine
learning-based solution, aiming to improve care for cancer patients
by giving cancer care teams access to complex data and
information
- The potentially transformative solution will initially focus on
ovarian cancer and will then expand for use in breast and kidney
cancer.
GE Healthcare, the University of Cambridge and Cambridge
University Hospitals have agreed to collaborate on developing an
application aiming to improve cancer care, with Cambridge providing
clinical expertise and data to support GE Healthcare’s development
and evaluation of an AI-enhanced application that integrates cancer
patient data from multiple sources into a single interface.
Building on research supported by The Mark Foundation for Cancer
Research and Cancer Research UK, the collaboration aims to address
the problems of fragmented or siloed data and disconnected patient
information, which is challenging for clinicians to manage
effectively and can prevent cancer patients receiving optimal
treatment.
“Thanks to ever-improving technologies, we now generate
increasing amounts of complex data for each patient with cancer.
These include multiple imaging scans, digital pathology, genomic
data, advanced blood tests and treatment information. Bringing all
this data together to make precise and informed decisions for
patients can be hard. We often do this inefficiently and miss
important connections between the data,” said Professor Richard
Gilbertson, Director of the Cancer Research UK Cambridge Centre,
and Head of the Department of Oncology at the University of
Cambridge.
This new application would be designed using advanced software
engineering and machine learning methods to integrate a variety of
patient data including clinical, imaging and genomic data - from
diagnosis through every stage of treatment - into one single
location. The aim is to offer all medical teams involved in a
patient’s cancer care - medical oncologists, clinical oncologists,
surgeons, radiologists, pathologists, clinical nurse specialists
and more - simultaneous access to the necessary data and
information to allow the medical team to plan the best, most
personalized treatment for each of their patients.
The application is expected to be evaluated for ovarian cancer
initially in Cambridge and the goal is to evaluate it across the
UK, and beyond. Ovarian cancer is often difficult to treat as most
patients present with advanced disease. Although initially 70-80%
of patients will respond well to chemotherapy, ultimately most
develop chemotherapy resistance leading to treatment failure.1 The
application may help clinicians have better visibility on how the
patient respond to treatment, thus helping them more effectively
identify when treatment may require adjustment. If the application
is successfully developed, our vision is for it to be expanded for
use in breast and kidney cancer patients.
“Healthcare professionals can struggle to easily find and
interpret the many different types of patient data information they
need to make the best clinical decisions,” said Dr Ben Newton, GM
Oncology at GE Healthcare. “Bringing these multiple data streams
into a single interface could enable clinicians to make fast,
informed and highly personalised treatment decisions throughout a
patient’s cancer care pathway.”
Two Addenbrooke’s cancer clinicians aiming to evaluate the
application to help patients are consultant oncologist Prof. James
Brenton, professor of Ovarian Cancer Medicine and a senior group
leader at the Cancer Research UK Cambridge Institute; and
consultant radiologist Prof. Evis Sala, professor of Oncological
Imaging, University of Cambridge.
“Aggregating and analysing the substantial amounts of data
available would help address an unmet need. Ovarian cancer is an
important and complex disease with poor outcomes, and we believe
this application would help us deal with its complexity.
Eventually, we hope to be able to better understand the disease and
therefore improve treatment and outcomes for patients,” says Prof.
Brenton, who co-leads the Mark Foundation Institute for Integrated
Cancer Medicine (MFICM) at the University of Cambridge.
“If we can aggregate and integrate relevant data along the care
pathway, and visualize the output, it may ultimately lead to
clinicians making better-informed decisions and better care.” adds
Prof. Sala who also co-leads the MFICM at the University of
Cambridge.
“The team aims to transform the delivery of cancer patient care
by integrating multiple data streams together into a single
platform that can be accessed simultaneously by clinicians,
patients and multi-disciplinary teams (MDTs) from tertiary and
regional hospitals.”
The development work will be underpinned by GE Healthcare’s
Edison platform to integrate data from diverse sources, such as
electronic health records (EHR) and radiology information systems
(RIS), imaging and other medical device data.
About GE Healthcare:
GE Healthcare is the $17* billion healthcare business of GE
(NYSE: GE). As a leading global medical technology, pharmaceutical
diagnostics and digital solutions innovator, GE Healthcare enables
clinicians to make faster, more informed decisions through
intelligent devices, data analytics, applications and services,
supported by its Edison intelligence platform. With over 100 years
of healthcare industry experience and around 47,000 employees
globally, the company operates at the center of an ecosystem
working toward precision health, digitizing healthcare, helping
drive productivity and improve outcomes for patients, providers,
health systems and researchers around the world.
Follow us on Facebook, LinkedIn, Twitter, and Insights for the
latest news, or visit our website www.gehealthcare.com for more
information.
*Excludes Biopharma business divested in March 2020.
About The University of Cambridge
The University of Cambridge is one of the world’s top ten
leading universities, with a rich history of radical thinking
dating back to 1209. Its mission is to contribute to society
through the pursuit of education, learning and research at the
highest international levels of excellence.
The University comprises 31 autonomous Colleges and 150
departments, faculties and institutions. Its 24,450 student body
includes more than 9,000 international students from 147 countries.
In 2020, 70.6% of its new undergraduate students were from state
schools and 21.6% from economically disadvantaged areas.
Cambridge research spans almost every discipline, from science,
technology, engineering and medicine through to the arts,
humanities and social sciences, with multi-disciplinary teams
working to address major global challenges. Its researchers provide
academic leadership, develop strategic partnerships and collaborate
with colleagues worldwide.
The University sits at the heart of the ‘Cambridge cluster’, in
which more than 5,300 knowledge-intensive firms employ more than
67,000 people and generate £18 billion in turnover. Cambridge has
the highest number of patent applications per 100,000 residents in
the UK.
www.cam.ac.uk
About Cambridge University Hospitals:
Cambridge University Hospitals NHS Foundation Trust (CUH) is one
of the largest and best known trusts in the country, delivering
high-quality patient care through Addenbrooke’s and the Rosie
Hospitals. CUH is a leading national centre for specialist
treatment for rare or complex conditions and a university teaching
hospital with a worldwide reputation.
CUH is a key partner in Cambridge University Health Partners
(CUHP), one of only six academic health science centres in the UK,
and is at the heart of the development of the Cambridge Biomedical
Campus (CBC), which brings together on one site world-class
biomedical research, patient care and education. As part of the
Campus development, Papworth Hospital has created a bespoke,
purpose-built hospital, and AstraZeneca is building a new global
R&D centre and corporate headquarters. The Campus is one of the
Government’s National Institute for Health Research (NIHR)
comprehensive biomedical research centres.
For further information about Cancer Research UK's work or to
find out how to support the charity, please call 0300 123 1022 or
visit www.cancerresearchuk.org. Follow us on Twitter and
Facebook.
1
https://www.integratedcancermedicine.org/research/disease-areas/ovarian-cancer/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211129005416/en/
GE Healthcare Hannah Huntly Hannah.huntly@ge.com +44 7887
824201
University of Cambridge Craig Brierley
Craig.Brierley@admin.cam.ac.uk Cancer Research UK Katie Edwards
katie.edwards@cruk.cam.ac.uk
Cambridge University Hospitals/ Addenbrookes Hospital
Sarah.Vincent@addenbrookes.nhs.uk
Grafico Azioni General Electric (NYSE:GE)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni General Electric (NYSE:GE)
Storico
Da Mar 2023 a Mar 2024